Gilead Sciences (GILD.US) acquires PepStar's oral inflammation drug project for $1.275 billion in cash, strengthening its inflammatory bowel disease pipeline.

智通财经2026/10/23 00:35

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zhihu Finance APP has learned that Gilead Sciences (GILD.US) announced on Thursday it will acquire PepStar Therapeutics’ oral inflammation drug program for an upfront cash payment of $1.275 billion, which includes an experimental gut disease therapy. This deal comes after Gilead’s experimental oral drug emvistegrast for chronic intestinal disease reported positive mid-stage results on Monday, adding another inflammatory bowel disease (IBD) candidate to its portfolio. Gilead stated it believes HCXT-2001 has potential either as a standalone development or in combination with other pipeline projects.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Anthropic plans to publicly offer shares to raise up to 64.4 billions USD, which is lower than the 69.3 billions USD in its previously withdrawn version. The offering price range is set at 70 to 78 USD per share. Seven tech giants, including Alphabet, Nvidia, and AMD, will separately invest a total of 26 billions USD through private placements. Based on the upper offering price of 78 USD, Anthropic's valuation would be around 102 billions USD.

华尔街见闻•2026/11/10 12:07